Get the app
US › Healthcare

Quince Therapeutics, Inc. (QNCX)

US · Healthcare · Biotechnology

$32.03-3.61%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-75.5M
EPS
$-12.31
EPS estimate
$-33.26

EPS came in at -12.31 against a street estimate of -33.26 — a beat of 63.0%.

Key statistics

Market cap
$32.3M
Forward P/E
0.0
P/B
2.21
Book value
$-34.73
EPS (TTM)
$-214.01
52-week high
$910.00
52-week low
$15.10
50-day MA
$30.65
200-day MA
$91.76
Beta
1.33

Analyst view

Analysts rate Quince Therapeutics, Inc. a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $75.00.

Shareholding

Insiders
2.90%
Institutions
34.49%

Largest institutional holders

FundStake
Ikarian Capital, LLC1.30%
Millennium Management LLC1.27%
Balyasny Asset Management LLC1.26%
Squadron Capital Management LLC0.72%
Shay Capital LLC0.31%
BOOTHBAY FUND MANAGEMENT, LLC0.25%
Jane Street Group LLC0.23%
Vanguard Capital Management, LLC0.22%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Quince Therapeutics, Inc. — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.